Ok Ercan, Asci Gulay, Bayraktaroglu Selen, Toz Huseyin, Ozkahya Mehmet, Yilmaz Mumtaz, Kircelli Fatih, Sevinc Ok Ebru, Ceylan Naim, Duman Soner, Cirit Mustafa, Monier-Faugere Marie-Claude, Malluche Hartmut H
Division of Nephrology and
Division of Nephrology and.
J Am Soc Nephrol. 2016 Aug;27(8):2475-86. doi: 10.1681/ASN.2015030268. Epub 2015 Dec 23.
Exposure to high Ca concentrations may influence the development of low-turnover bone disease and coronary artery calcification (CAC) in patients on hemodialysis (HD). In this randomized, controlled study, we investigated the effects of lowering dialysate Ca level on progression of CAC and histologic bone abnormalities in patients on HD. Patients on HD with intact parathyroid hormone levels ≤300 pg/ml receiving dialysate containing 1.75 or 1.50 mmol/L Ca (n=425) were randomized to the 1.25-mmol/L Ca (1.25 Ca; n=212) or the 1.75-mmol/L Ca (1.75 Ca; n=213) dialysate arm. Primary outcome was a change in CAC score measured by multislice computerized tomography; main secondary outcome was a change in bone histomorphometric parameters determined by analysis of bone biopsy specimens. CAC scores increased from 452±869 (mean±SD) in the 1.25 Ca group and 500±909 in the 1.75 Ca group (P=0.68) at baseline to 616±1086 and 803±1412, respectively, at 24 months (P=0.25). Progression rate was significantly lower in the 1.25 Ca group than in the 1.75 Ca group (P=0.03). The prevalence of histologically diagnosed low bone turnover decreased from 85.0% to 41.8% in the 1.25 Ca group (P=0.001) and did not change in the 1.75 Ca group. At 24 months, bone formation rate, trabecular thickness, and bone volume were higher in the 1.25 Ca group than in the 1.75 Ca group. Thus, lowering dialysate Ca levels slowed the progression of CAC and improved bone turnover in patients on HD with baseline intact parathyroid hormone levels ≤300 pg/ml.
血液透析(HD)患者暴露于高钙浓度可能会影响低转换骨病和冠状动脉钙化(CAC)的发展。在这项随机对照研究中,我们调查了降低透析液钙水平对HD患者CAC进展和组织学骨异常的影响。将甲状旁腺激素水平≤300 pg/ml且接受含1.75或1.50 mmol/L钙透析液的HD患者(n = 425)随机分为1.25 mmol/L钙(1.25 Ca;n = 212)或1.75 mmol/L钙(1.75 Ca;n = 213)透析液组。主要结局是通过多层计算机断层扫描测量的CAC评分变化;主要次要结局是通过骨活检标本分析确定的骨组织形态计量学参数变化。在基线时,1.25 Ca组的CAC评分为452±869(平均值±标准差),1.75 Ca组为500±909(P = 0.68),到24个月时分别为616±1086和803±1412(P = 0.25)。1.25 Ca组的进展率显著低于1.75 Ca组(P = 0.03)。组织学诊断为低骨转换的患病率在1.25 Ca组从85.0%降至41.8%(P = 0.001),在1.75 Ca组未发生变化。在24个月时,1.25 Ca组的骨形成率、小梁厚度和骨体积高于1.75 Ca组。因此,降低透析液钙水平可减缓基线甲状旁腺激素水平≤300 pg/ml的HD患者的CAC进展并改善骨转换。